Skip to main content
. 2017 Aug 29;7:9847. doi: 10.1038/s41598-017-08587-6

Table 1.

Summary of the sequence assembly for each treatment group.

Samples Total reads Total nucleotides (bp) GC% Q30%
Control-1 22,498,116 3,374,717,400 52.59 95.34
Control-2 28,105,672 4,215,850,800 52.68 95.38
F5D1-1 23,992,856 3,598,928,400 52.85 95.4
F5D1-2 31,759,734 4,763,960,100 53 95.34
F5D3-1 25,744,530 3,861,679,500 52.23 95.3
F5D3-2 27,129,926 4,069,488,900 52.37 95.36
F20D1-1 25,418,168 3,812,725,200 52.65 95.33
F20D1-2 31,876,778 4,781,516,700 53.36 95.34
F20D3-1 26,754,336 4,013,150,400 52.75 95.25
F20D3-2 27,129,926 4,093,988,400 52.86 95.3
Average 27,041,004 4,058,600,580 53 95

Control: sample collected before F treatment; F5D1: 5 mg/L F for 1 day; F5D3: 5 mg/L F for 3 days; F20D1: 20 mg/L F for 1 day; F20D3: 20 mg/L F for 3 days; 1 and 2 for biological replicates.